VRTX240719C360000
- 113.65
- 0.000.00%
Vertex Pharmaceuticals Newsroom
Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A
Insider Sale: EVP and CMO Carmen Bozic Sells Shares of Vertex Pharmaceuticals Inc (VRTX)
On July 10, 2024, Carmen Bozic, Executive Vice President and Chief Medical Officer of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), sold 2,280 shares of the company.
Forecasting The Future: 13 Analyst Projections For Vertex Pharmaceuticals
In the preceding three months, 13 analysts have released ratings for Vertex Pharmaceuticals (NASDAQ:VRTX), presenting a wide array of perspectives from bullish to bearish.The table below provides a
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 -7.67% Morgan Stanley $402 → $455 Maintains Equal-Weight 06/27/2024 10.59% Redburn Atlantic → $
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
New York, USA, July 11, 2024 (GLOBE NEWSWIRE) -- Cystic Fibrosis Market is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech,
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Trading At A 28% Discount?
Today we will run through one way of estimating the intrinsic value of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by taking the expected future cash flows and discounting them to their present value.
Express News | Vertex Pharmaceuticals Inc : Morgan Stanley Raises Target Price to $455 From $402
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $455 From $402
Vertex Pharmaceuticals (VRTX) has an average rating of outperform and price targets ranging from $325 to $577, according to analysts by Capital IQ.Price: 491.00, Change: -0.62, Percent Change: -0.13
Check Out What Whales Are Doing With VRTX
High-rolling investors have positioned themselves bullish on Vertex Pharmaceuticals (NASDAQ:VRTX), and it's important for retail traders to take note.\This activity came to our attention today
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 1.11 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 10, $Vertex Pharmaceuticals(VRTX.US)$ Officer Bozic Carmen intends to sell 2,280 shares of its common stock on Jul 10, with a total market value of approximately $1.11
Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $485.99, marking a +0.85% move from the previous day.
Vertex Pharmaceuticals Hits 4-week High
Express News | Vertex Pharmaceuticals Inc : RBC Raises Target Price to $431 From $421
Prediction: This Will Be Vertex Pharmaceuticals' New Billion-Dollar Growth Driver (and It's Coming Soon).
Vertex's (VRTX.US) new generation small molecule combination therapy has received FDA and EMA approval for market application.
It is reported that the Zhitongcaijing APP learned that Vertex Pharmaceuticals (VRTX.US) announced that the U.S. FDA has accepted its new drug application (NDA) for once-daily vanczaftor/tezacaftor/deutivacaftor triple therapy (Vanza Triple Therapy) for the treatment of cystic fibrosis (CF) patients aged 6 and above. These patients have at least one F508del mutation or another responsive mutation in the CFTR gene. Patients with these mutations respond to Van
FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) said Tuesday that the US Food and Drug Administration has accepted its new-drug application for the combination therapy of vanzacaftor, tezacaftor, and deutivacaftor to t
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy
By Colin Kellaher Vertex Pharmaceuticals has won Food and Drug Administration priority review for its application seeking approval of a triple combination therapy for the genetic lung disease cystic
Express News | Vertex Pharmaceuticals Announces FDA Acceptance Of NDA For Vanza Triple Therapy With Priority Review, PDUFA Target Date Set For January 2, 2025; EU Marketing Authorization Application Also Validated By EMA For Cystic Fibrosis Treatment
Express News | Vertex Pharmaceuticals Inc: EU Marketing Authorization Application (Maa) Submission Validated by EMA